Niquitin Menta (Nicotine)

Nicotine, the active ingredient in Niquitin Menta, is a nicotinic receptor agonist presented as an oromucosal formulation for oromucosal use. It helps adult smokers manage nicotine withdrawal and reduce cravings.

GNH USA supplies Niquitin Menta as a licensed, GDP-compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Niquitin Menta acts on the nicotinic acetylcholine receptor system to aid individuals seeking to stop tobacco use.

- Smoking cessation: assists adult smokers in quitting by reducing withdrawal symptoms and cravings. - Nicotine dependence: alleviates cravings associated with nicotine addiction.

Niquitin Menta may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Mouth irritation: discomfort or soreness in the oral cavity. - Nausea: feeling of queasiness or upset stomach. - Dizziness: light‑headed sensation, especially after initial use. - Headache: mild to moderate head pain. - Hiccups: involuntary diaphragm contractions. - Throat irritation: scratchy or sore throat.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, palpitations, or hypertension. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Arrhythmia: irregular heart rhythm. - Seizures: rare neurologic episodes. - Prolonged hypertension: sustained high blood pressure.

Before using Niquitin Menta, consider the following safety measures.

- Assess cardiovascular status: evaluate for hypertension or heart disease prior to initiation. - Avoid use in uncontrolled asthma: nicotine may exacerbate bronchospasm. - Monitor for signs of dependence: prolonged use can lead to nicotine addiction. - Pregnancy and lactation: consult a healthcare professional before use. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Niquitin Menta can interact with several medication classes; awareness helps minimize risk.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase hypertensive risk. - Beta‑blockers: nicotine may blunt expected cardiovascular response; monitor closely. - CYP2A6 inhibitors: can alter nicotine metabolism and increase exposure.

Moderate Interactions (Monitor Closely): - Alcohol: may enhance central nervous system effects. - Selective serotonin reuptake inhibitors (SSRIs): monitor for increased side‑effects. - Antihypertensives: nicotine may reduce their efficacy, requiring dose adjustment.